The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
Saved in:
Main Authors: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Complementary Medicine and Therapies |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12906-025-04753-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patterns of cannabidiol use among marijuana users in the United States
by: Ji-Yeun Park
Published: (2025-02-01) -
Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer’s Disease: A Systematic Review
by: Joanna Campbell, et al.
Published: (2024-11-01) -
A nomogram prediction model for mild cognitive impairment in non-dialysis outpatient patients with chronic kidney disease
by: Qin Yang, et al.
Published: (2024-12-01) -
Potential cytotoxic effect of cannabidiol against human glioblastoma cells in vitro
by: Justyna Lasota, et al.
Published: (2024-09-01) -
Feasibility pilot of a novel coaching intervention to optimize cannabis use for chronic pain management among Veterans
by: Kevin F. Boehnke, et al.
Published: (2025-01-01)